Personalised medicine in CNS malignancies

Speaker: Matthias Preuser

M. Preusser discusses the molecular markers that should be routinely assessed and biomarker-driven algorithm for glioma treatment. Furthermore, he covers currently standardised molecular techniques, importance of quality control in molecular testing, and molecular markers that are currently under investigation in glioma and other primary brain tumours.

Discussion Points

  • Which molecular markers should be routinely assessed in patients with glioma?
  • When should patients be tested? Which molecular techniques are currently standardised?
  • Which markers other then standard molecular testing are being investigated?
  • What is the current perspective for biological treatment of glioma?
  • Where do we stand on molecular testing in other primary brain tumours?